A client with intermittent claudication has heart failure wi… | MyMerci
Adverse Effects/Contraindications/Interactions PPT
Question

A client with intermittent claudication has heart failure with reduced ejection fraction. Which new prescription should the nurse clarify?

Explanation
Cilostazol is contraindicated in heart failure of any severity because phosphodiesterase III inhibitors have been associated with decreased survival in class III to IV heart failure.
Next question on this topicA nurse is reviewing the morning lab results for an adult client receiving warfarin for at…

In-depth explanation

Quick answer
Clarify cilostazol in any client with heart failure.

Why this is correct
The claudication indication does not override the boxed heart-failure contraindication.

Easy analogy or mental picture
Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.

Memory hook
Drug, urgent cue, protective action, and reassessment endpoint.

NCLEX decision rule
Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.

Why the other choices are wrong
Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
References
1DailyMed: Cilostazol TabletsHeart-failure contraindication and claudication indication

Clinical scenario

Medication-safety review
Verify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.
Browse all questions No login required

Master the NCLEX-RN with MyMerci

Thousands of NCLEX-style questions with detailed rationale — in your language. Track your progress and study smarter.

Start for free
App Store Google Play
Read in another language: English한국어日本語繁體中文Tiếng Việt

For study reference only. Always follow current clinical guidelines and your institution’s protocols.